LT3034075T - Imidazotriazinai ir imidazopirimidinai kaip kinazės inhibitoriai - Google Patents

Imidazotriazinai ir imidazopirimidinai kaip kinazės inhibitoriai

Info

Publication number
LT3034075T
LT3034075T LTEP15191241.7T LT15191241T LT3034075T LT 3034075 T LT3034075 T LT 3034075T LT 15191241 T LT15191241 T LT 15191241T LT 3034075 T LT3034075 T LT 3034075T
Authority
LT
Lithuania
Prior art keywords
imidazotriazines
imidazopyrimidines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
LTEP15191241.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jincong Zhuo
Brian Metcalf
Meizhong Xu
Chunhong He
Colin Zhang
Ding-Quan Qian
David M. Burns
Yunlong Li
Wenqing Yao
Original Assignee
Incyte Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3034075(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corporation filed Critical Incyte Holdings Corporation
Publication of LT3034075T publication Critical patent/LT3034075T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP15191241.7T 2006-11-22 2007-11-19 Imidazotriazinai ir imidazopirimidinai kaip kinazės inhibitoriai LT3034075T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86084006P 2006-11-22 2006-11-22
US86145906P 2006-11-29 2006-11-29
US95723607P 2007-08-22 2007-08-22

Publications (1)

Publication Number Publication Date
LT3034075T true LT3034075T (lt) 2018-11-26

Family

ID=39166437

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP15191241.7T LT3034075T (lt) 2006-11-22 2007-11-19 Imidazotriazinai ir imidazopirimidinai kaip kinazės inhibitoriai
LTPA2022527C LTC2099447I2 (OSRAM) 2006-11-22 2022-12-13

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2022527C LTC2099447I2 (OSRAM) 2006-11-22 2022-12-13

Country Status (37)

Country Link
US (8) US7767675B2 (OSRAM)
EP (4) EP3443958A1 (OSRAM)
JP (1) JP5572388B2 (OSRAM)
KR (2) KR101588583B1 (OSRAM)
CN (2) CN101641093B (OSRAM)
AR (1) AR066142A1 (OSRAM)
AU (1) AU2007323725B2 (OSRAM)
BR (1) BRPI0719333A2 (OSRAM)
CA (1) CA2669991C (OSRAM)
CL (1) CL2007003341A1 (OSRAM)
CO (1) CO6210810A2 (OSRAM)
CR (1) CR10841A (OSRAM)
CY (4) CY1116763T1 (OSRAM)
DK (3) DK2099447T3 (OSRAM)
EA (2) EA032254B1 (OSRAM)
EC (1) ECSP099400A (OSRAM)
ES (3) ES2398843T3 (OSRAM)
FR (1) FR22C1060I2 (OSRAM)
GE (1) GEP20125658B (OSRAM)
HK (1) HK1225978B (OSRAM)
HR (3) HRP20130106T1 (OSRAM)
HU (2) HUE026659T2 (OSRAM)
IL (4) IL198716A (OSRAM)
LT (2) LT3034075T (OSRAM)
LU (1) LUC00293I2 (OSRAM)
ME (2) ME01507B (OSRAM)
MX (1) MX2009005144A (OSRAM)
MY (2) MY188335A (OSRAM)
NL (1) NL301209I2 (OSRAM)
NO (4) NO346024B1 (OSRAM)
NZ (1) NZ577127A (OSRAM)
PL (3) PL2099447T3 (OSRAM)
PT (3) PT2497470E (OSRAM)
RS (3) RS52677B (OSRAM)
SI (3) SI3034075T1 (OSRAM)
TW (1) TWI429432B (OSRAM)
WO (1) WO2008064157A1 (OSRAM)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2474545T (pt) 2005-12-13 2017-02-14 Incyte Holdings Corp Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase
EP2010493B1 (en) 2006-04-12 2016-01-27 Merck Sharp & Dohme Corp. Pyridyl amide t-type calcium channel antagonists
US7683060B2 (en) * 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
MY188335A (en) 2006-11-22 2021-11-30 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
GEP20125533B (en) 2007-06-13 2012-05-25 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentyl propanenitrile
MX2010004530A (es) * 2007-10-24 2010-05-14 Merck Sharp & Dohme Antagonistas de los canales de calcio tipo t de heterociclo fenil amida.
CN102015716B (zh) 2008-02-28 2014-09-17 诺华股份有限公司 用于治疗C-Met酪氨酸激酶介导的疾病的咪唑并[1,2-b]哒嗪衍生物
BRPI0912882A2 (pt) * 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
WO2010002472A1 (en) * 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
FR2933982A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CA2752105C (en) * 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
HRP20192203T1 (hr) 2009-05-22 2020-03-06 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012008061A2 (pt) * 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
RS63612B1 (sr) 2009-12-31 2022-10-31 Hutchison Medipharma Ltd Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
JP5714030B2 (ja) * 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
US8518945B2 (en) * 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
JP5816678B2 (ja) * 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
MX2012011941A (es) * 2010-04-14 2013-08-27 Array Biopharma Inc Imidazo [1, 2-c] pirimidinas 5, 7-substituidas como inhibidores de jak cinasas.
EA025281B9 (ru) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR20140019300A (ko) 2010-11-19 2014-02-14 인사이트 코포레이션 Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
TW201242965A (en) 2011-02-01 2012-11-01 Kyowa Hakko Kirin Co Ltd Ring-fused heterocyclic derivative
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
MY179332A (en) 2011-09-02 2020-11-04 Incyte Holdings Corp Heterocyclylamines as pl3k inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
PH12014500730A1 (en) * 2011-10-12 2018-01-17 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
CN107898790B (zh) 2011-11-30 2024-06-21 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2833917A1 (en) 2012-04-03 2015-02-11 Novartis AG Tyrosine kinase inhibitor combinations and their use
EP3964513A1 (en) * 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
RU2705095C2 (ru) * 2012-08-16 2019-11-05 Новартис Аг Комбинация ингибитора pik3 и ингибитора с-мет
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
BR122021015061B1 (pt) 2013-03-06 2022-10-18 Incyte Holdings Corporation Processos e intermediários para preparar um inibidor de jak
CN107312009B (zh) * 2013-04-17 2022-09-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
LT3122358T (lt) 2014-03-26 2021-04-12 Astex Therapeutics Ltd. Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
EA039220B1 (ru) * 2014-07-25 2021-12-20 Новартис Аг СОСТАВ ТАБЛЕТКИ 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
PE20171514A1 (es) * 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
EP3831833B1 (en) 2015-02-27 2022-10-26 Incyte Holdings Corporation Processes for the preparation of a pi3k inhibitor
CA2979215A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
CN106715440B (zh) 2015-04-21 2019-02-22 江苏恒瑞医药股份有限公司 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
PT3297992T (pt) 2015-05-22 2020-03-17 Chong Kun Dang Pharmaceutical Corp Compostos derivados de alquilo heterocíclicos como inibidores seletivos da histona desacetilase e composições farmacêuticas que compreendem os mesmos
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
RU2018125603A (ru) * 2015-12-17 2020-01-21 Новартис Аг Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
CN108697694B (zh) 2016-01-27 2022-12-09 苏黎世大学 Gabaa受体调节剂用于治疗发痒的用途
HUE064656T2 (hu) * 2016-03-28 2024-04-28 Incyte Corp Pirrolotriazin vegyületek mint TAM inhibitorok
MX387322B (es) 2016-04-22 2025-03-18 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
US11213520B2 (en) * 2016-05-23 2022-01-04 Boehringer Ingelheim International Gmbh Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496000A (zh) * 2016-10-19 2017-03-15 蚌埠学院 一种3‑氟‑4‑溴‑苯乙酮的合成方法
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CU24606B1 (es) 2017-06-22 2022-06-06 Novartis Ag Moléculas de anticuerpo que se unen a cd73
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
SMT202200011T1 (it) 2017-09-27 2022-03-21 Incyte Corp Sali di derivati di pirrolotriazina utili come inibitori di tam
US11730810B2 (en) 2017-11-14 2023-08-22 Children's Medical Center Corporation Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response
EP3709998B8 (en) 2017-11-14 2025-02-19 Children's Medical Center Corporation N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
PL3773593T3 (pl) 2018-03-30 2024-09-02 Incyte Corporation Leczenie ropnego zapalenia gruczołów potowych z zastosowaniem inhibitorów jak
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
CN110526916B (zh) * 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
CN108530337B (zh) * 2018-06-25 2020-11-03 南华大学 一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
KR102839002B1 (ko) 2018-06-29 2025-07-29 인사이트 코포레이션 Axl/mer 억제제의 제형
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020069418A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
BR112021011948A2 (pt) * 2018-12-20 2021-09-08 Incyte Corporation Compostos de imidazopiridazina e imidazopiridina e usos dos mesmos
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
BR112022011998A2 (pt) 2019-12-20 2022-08-30 Novartis Ag Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111825678A (zh) * 2020-06-05 2020-10-27 连庆泉 一种卡马替尼的制备方法
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024532374A (ja) 2021-09-01 2024-09-05 ノバルティス アーゲー Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
CN113896732B (zh) * 2021-10-13 2023-09-12 沈阳红旗制药有限公司 抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN116903627B (zh) * 2023-05-15 2024-01-16 云白药征武科技(上海)有限公司 一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411859A (en) 1920-12-08 1922-04-04 Marchand Robert Process for preparing hydrate of terpin
US2837520A (en) * 1955-05-26 1958-06-03 Ind Chimica Profarmaco S R L Fluorescent materials on the basis of tetrazoindenes
US4209621A (en) * 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de) 1983-03-31 1984-10-04 Hoechst Ag, 6230 Frankfurt Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
JPS6337347A (ja) 1986-08-01 1988-02-18 Fuji Photo Film Co Ltd 直接ポジカラ−画像形成方法
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja) 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja) 1990-02-15 1997-10-15 富士写真フイルム株式会社 ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja) 1991-01-09 1992-09-07 Konica Corp ハロゲン化銀写真感光材料
FR2671551B1 (fr) * 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5232618A (en) 1991-09-30 1993-08-03 E. I. Du Pont De Nemours And Company Substantially constant boiling compositions of difluoromethane and trifluoroethane or perfluoroethane
JPH05232618A (ja) 1992-02-21 1993-09-10 Konica Corp ハロゲン化銀写真感光材料
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
HRP980375A2 (en) * 1997-07-03 1999-04-30 Argyrios Georgios Arvanitis Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
DE19734311A1 (de) 1997-08-08 1999-02-11 Bosch Gmbh Robert Anordnung zur Übertragung optischer Signale mit Ersatzschaltungswirkung
JP4251243B2 (ja) 1998-11-26 2009-04-08 株式会社日立メディコ 領域拡張装置
JP4025468B2 (ja) 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
AU784484B2 (en) 1999-11-10 2006-04-13 Ortho-Mcneil Pharmaceutical, Inc. Substituted 2-aryl-3(heteroaryl)-imidazo(1,2-a) pyrimidines, and related pharmaceutical compositions and methods
ATE236158T1 (de) 1999-11-12 2003-04-15 Neurogen Corp Bicyclische und tricyclische heteroaromatische verbindungen
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
DE60115282T2 (de) 2000-11-10 2006-08-10 Merck Sharp & Dohme Ltd., Hoddesdon Imidazotriazin-derivate als liganden für gaba-rezeptoren
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
BR0207990A (pt) 2001-03-09 2004-04-27 Pfizer Prod Inc Compostos antinflamatórios de triazolopiridinas
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
KR20040000507A (ko) 2001-05-24 2004-01-03 야마노우치세이야쿠 가부시키가이샤 3-퀴놀린-2(1ｈ)-일리덴인돌린-2-온 유도체
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
CA2476757A1 (en) * 2002-03-01 2003-09-12 Yamanouchi Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound
WO2003080621A1 (en) 2002-03-19 2003-10-02 Merck & Co., Inc. Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210127D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
WO2004020438A2 (en) 2002-08-30 2004-03-11 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
RU2005122484A (ru) 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US20060173009A1 (en) 2003-01-07 2006-08-03 Hiroyuki Kanoh Agent inducing increase in bone mass
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
ES2502490T3 (es) 2003-02-26 2014-10-03 Sugen, Inc. Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
MXPA06000091A (es) 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
BRPI0412040A (pt) 2003-07-02 2006-09-05 Sugen Inc hidrazidas de indolinona como inibidores de c-met
WO2005014598A1 (en) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
WO2005040345A2 (en) 2003-09-24 2005-05-06 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
US7144889B2 (en) * 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
CA2556404A1 (en) 2004-02-18 2005-08-25 Banyu Pharmaceutical Co., Ltd. Nitrogenous fused heteroaromatic ring derivative
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
US20050277650A1 (en) 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
MY139689A (en) * 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
JP2008508303A (ja) * 2004-07-27 2008-03-21 エスジーエックス ファーマシューティカルズ、インコーポレイテッド ピロロ−ピリジンキナーゼモジュレーター
NZ552866A (en) * 2004-08-26 2010-06-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006044509A2 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JP4935357B2 (ja) * 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｘｉａ因子阻害剤としての置換ビアリール化合物
JP2008540535A (ja) * 2005-05-12 2008-11-20 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
JP2009500451A (ja) 2005-07-11 2009-01-08 スミスクライン ビーチャム コーポレーション ピラノピリジン化合物
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
BRPI0619252A2 (pt) 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
ME02736B (me) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
DK2495016T3 (da) 2005-12-23 2019-12-16 Ariad Pharma Inc Bicykliske heteroarylforbindelser
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
KR101083177B1 (ko) 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
MY188335A (en) 2006-11-22 2021-11-30 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
CA2688823A1 (en) 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
BRPI0912882A2 (pt) 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
EP2706063A4 (en) 2011-05-06 2015-03-25 Takasago Perfumery Co Ltd RUTHENIUM DIAMINE COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS

Also Published As

Publication number Publication date
NO344864B1 (no) 2020-06-02
IL284889B2 (en) 2023-05-01
EA201691862A2 (ru) 2017-09-29
AU2007323725B2 (en) 2014-02-20
US20180282340A1 (en) 2018-10-04
EP2099447A1 (en) 2009-09-16
CY1117108T1 (el) 2017-04-05
PT2099447E (pt) 2013-02-27
IL284889B1 (en) 2023-01-01
CA2669991A1 (en) 2008-05-29
CN103288833B (zh) 2018-01-12
CN101641093B (zh) 2013-05-29
US9944645B2 (en) 2018-04-17
NZ577127A (en) 2012-03-30
CN101641093A (zh) 2010-02-03
CR10841A (es) 2009-06-30
KR101588583B1 (ko) 2016-01-28
US20160326178A1 (en) 2016-11-10
NO346024B1 (no) 2022-01-03
EA032254B1 (ru) 2019-04-30
PL3034075T3 (pl) 2019-03-29
US11261191B2 (en) 2022-03-01
HUS2200052I1 (hu) 2023-01-28
US20130324515A1 (en) 2013-12-05
DK2497470T3 (en) 2015-12-07
HK1175700A1 (en) 2013-07-12
PL2497470T3 (pl) 2016-04-29
PL2099447T3 (pl) 2013-06-28
EP2099447B1 (en) 2012-11-07
IL284889A (en) 2021-08-31
EA200970501A1 (ru) 2009-12-30
PT3034075T (pt) 2018-11-05
IL198716A0 (en) 2010-02-17
US7767675B2 (en) 2010-08-03
ES2689444T3 (es) 2018-11-14
GEP20125658B (en) 2012-10-10
CY1121021T1 (el) 2020-05-29
IL276928A (en) 2020-10-29
CL2007003341A1 (es) 2008-04-18
EP3034075B1 (en) 2018-07-25
AR066142A1 (es) 2009-07-29
HRP20181622T1 (hr) 2018-12-14
US12084449B2 (en) 2024-09-10
KR101532256B1 (ko) 2015-06-29
AU2007323725A1 (en) 2008-05-29
JP5572388B2 (ja) 2014-08-13
FR22C1060I2 (fr) 2023-11-17
EP3034075A1 (en) 2016-06-22
NO344399B1 (no) 2019-11-25
CN103288833A (zh) 2013-09-11
ME01507B (me) 2014-04-20
NO20190709A1 (no) 2009-07-28
RS54510B1 (sr) 2016-06-30
HRP20160077T1 (hr) 2016-02-12
HK1225978B (en) 2017-09-22
SI2497470T1 (sl) 2016-02-29
US20200317680A1 (en) 2020-10-08
KR20090094299A (ko) 2009-09-04
ECSP099400A (es) 2009-07-31
IL276928B (en) 2022-03-01
MY188335A (en) 2021-11-30
NO20200077A1 (no) 2009-07-28
ES2560435T3 (es) 2016-02-19
NO2022057I1 (no) 2022-12-13
US20250223291A1 (en) 2025-07-10
PT2497470E (pt) 2016-02-22
CO6210810A2 (es) 2010-10-20
ES2398843T3 (es) 2013-03-22
MY188338A (en) 2021-11-30
MX2009005144A (es) 2009-05-27
DK3034075T3 (en) 2018-10-22
US10738052B2 (en) 2020-08-11
EA201691862A3 (ru) 2017-12-29
IL244244B (en) 2020-09-30
US20230002392A1 (en) 2023-01-05
LTC2099447I2 (OSRAM) 2025-04-25
JP2010510319A (ja) 2010-04-02
TWI429432B (zh) 2014-03-11
US20110136781A1 (en) 2011-06-09
CY1116763T1 (el) 2017-03-15
NO20091924L (no) 2009-07-28
DK2099447T3 (da) 2013-02-18
SI3034075T1 (sl) 2018-12-31
EP2497470A1 (en) 2012-09-12
ME02372B (me) 2016-06-20
EP2497470B1 (en) 2015-10-28
TW200835481A (en) 2008-09-01
HRP20130106T1 (hr) 2013-03-31
WO2008064157A1 (en) 2008-05-29
US20080167287A1 (en) 2008-07-10
CY2022037I1 (el) 2023-01-27
US8461330B2 (en) 2013-06-11
NL301209I1 (nl) 2022-12-21
CA2669991C (en) 2016-01-26
LUC00293I2 (OSRAM) 2024-10-04
RS57741B1 (sr) 2018-12-31
SI2099447T1 (sl) 2013-03-29
FR22C1060I1 (fr) 2023-02-03
EP2497470B8 (en) 2015-12-02
IL244244A0 (en) 2016-04-21
IL198716A (en) 2016-03-31
HUE026659T2 (en) 2016-07-28
RS52677B (sr) 2013-06-28
BRPI0719333A2 (pt) 2014-02-04
NL301209I2 (nl) 2023-01-24
EP3443958A1 (en) 2019-02-20
EA026126B1 (ru) 2017-03-31
HK1136489A1 (en) 2010-07-02
CY2022037I2 (el) 2023-03-24
KR20150014476A (ko) 2015-02-06

Similar Documents

Publication Publication Date Title
IL284889A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ZA200901073B (en) Kinase inhibitor
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
ZA200900109B (en) Pyrrolotriazine kinase inhibitors
IL197231A0 (en) Pyrimidines derivatives and their use as kinase inhibitors
IL190078A0 (en) Kinase inhibitors
PT2402319T (pt) Inibidores de dgat
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
EP2015745A4 (en) MACROCYCLIC KINASE INHIBITORS
IL196337A0 (en) Tyrosine kinase inhibitors
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
PL1943243T3 (pl) Inhibitory kinazy
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
IL197981A0 (en) Kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
GB0621719D0 (en) Ikk- serine-threonine protein kinase inhibitors
ZA200803287B (en) Kinase inhibitors
IL189985A0 (en) Kinase inhibitors
HK1120508A (en) Kinase inhibitors
GB0622367D0 (en) Phosphodiesterase inhibitors